|Videos|April 27, 2017
Advancing Innovative Technology into Safe and Effective Medicines
Advertisement
Episodes in this series
Larry Altstiel, MD, PhD, EVP, Chief Medical Officer, vTv Therapeutics also discussed their team’s programs in type 2 diabetes surrounding an activator of an enzyme called glucokinase and a glucagon-like receptor agonist. “GLP-1s right now are all injectables, and they all have side effects of nausea and vomiting. In our particular case, ours is an oral molecule, and it also doesn’t seem to have the gastrointestinal side effects.”
Advertisement
Related to this article
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Advertisement
Advertisement
Trending on HCPLive
1
New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity
2
Remibrutinib Receives FDA Approval for Symptomatic Dermographism
3
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
4
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
5